UM

Browse/Search Results:  1-8 of 8 Help

Selected(0)Clear Items/Page:    Sort:
A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma Journal article
Wang, Weidong, Lv, Wang, Wang, Hui, Xu, Yang, Yan, Junrong, Shen, Han Ming, Shan, Liqun, Hu, Jian. A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma[J]. Genes and Diseases, 2023, 10(6), 2241-2244.
Authors:  Wang, Weidong;  Lv, Wang;  Wang, Hui;  Xu, Yang;  Yan, Junrong; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0  IF:6.9/7.2 | Submit date:2024/01/10
Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment Journal article
Li,Guodong, Huang,Qi, Wai Wong,Vincent Kam, Wang,Wanhe, Leung,Chung Hang. Development of a dual targeting scaffold of SET7/MLL inhibitor for castration-resistant prostate cancer treatment[J]. Genes and Diseases, 2023, 10(6), 2260 - 2262.
Authors:  Li,Guodong;  Huang,Qi;  Wai Wong,Vincent Kam;  Wang,Wanhe;  Leung,Chung Hang
Favorite | TC[WOS]:3 TC[Scopus]:4  IF:6.9/7.2 | Submit date:2023/08/03
A novel acquired EGFR-SEPT14 fusion confers differential drug resistance to EGFR inhibitors in lung adenocarcinoma Other
2023-04-24
Authors:  Weidong Wang;  Wang Lv;  Hui Wang;  Yang Xu;  Junrong Yan; et al.
Favorite | TC[WOS]:0 TC[Scopus]:0 | Submit date:2023/08/03
Etiological roles of core promoter variation in triple-negative breast cancer Journal article
Huang, Teng, Li, Jiaheng, Wang, San Ming. Etiological roles of core promoter variation in triple-negative breast cancer[J]. Genes & Diseases, 2023, 10(1), 228 - 238.
Authors:  Huang, Teng;  Li, Jiaheng;  Wang, San Ming
Favorite | TC[WOS]:2 TC[Scopus]:3  IF:6.9/7.2 | Submit date:2022/05/17
Core Promoter  Rna-seq  Triple-negative Breast Cancer  Variation  Whole Exome Sequencing  
The multifaceted role of placental growth factor in the pathogenesis and progression of bronchial asthma and pulmonary fibrosis: Therapeutic implications Journal article
Huang, Dan, Liu, Gege, Xu, Zhiyi, Chen, Shushu, Wang, Cuili, Liu, Dewei, Cao, Jiahao, Cheng, Junfen, Wu, Bin, Wu, Dong. The multifaceted role of placental growth factor in the pathogenesis and progression of bronchial asthma and pulmonary fibrosis: Therapeutic implications[J]. Genes and Diseases, 2022.
Authors:  Huang, Dan;  Liu, Gege;  Xu, Zhiyi;  Chen, Shushu;  Wang, Cuili; et al.
Favorite | TC[WOS]:4 TC[Scopus]:4 | Submit date:2023/01/30
AHR  Airway remodeling  Bronchial asthma  Chronic airway inflammation  PlGF  
Development of an orally bioavailable selective inhibitor of the menin-MLL Journal article
Zhong, Hai Jing, Wang, Wanhe, Zhou, Wei, Liang, Jia Xin, Cheng, Yung Chi, Ma, Dik Lung, Leung, Chung Hang. Development of an orally bioavailable selective inhibitor of the menin-MLL[J]. Genes and Diseases, 2022, 10(5), 1735-1738.
Authors:  Zhong, Hai Jing;  Wang, Wanhe;  Zhou, Wei;  Liang, Jia Xin;  Cheng, Yung Chi; et al.
Favorite | TC[WOS]:1 TC[Scopus]:1  IF:6.9/7.2 | Submit date:2023/01/30
Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells Journal article
Shasha Cheng, Guan-Jun Yang, Wanhe Wang, Dik-Lung Ma, Chung-Hang Leung. Discovery of a tetrahydroisoquinoline-based CDK9-cyclin T1 protein–protein interaction inhibitor as an anti-proliferative and anti-migration agent against triple-negative breast cancer cells[J]. Genes & Diseases, 2021, 9(6), 1674-1688.
Authors:  Shasha Cheng;  Guan-Jun Yang;  Wanhe Wang;  Dik-Lung Ma;  Chung-Hang Leung
Favorite | TC[WOS]:23 TC[Scopus]:26  IF:6.9/7.2 | Submit date:2022/05/13
Cancer Stem Cells  Cdk9-cyclin T1  Epithelial Mesenchymal Transition  Protein–protein Interaction (Ppi)  Triple-negative Breast Cancer (Tnbc)  
Highly mutable core promoters in triple-negative breast cancer Journal article
Wang, S. M.. Highly mutable core promoters in triple-negative breast cancer[J]. Genes and Diseases.
Authors:  Wang, S. M.
Favorite |  | Submit date:2022/07/27
promoter  mutation  cancer  expression